Payment overview · 2025
General Payments
$4,492.44
128 reported records · 22 companies
Healthcare provider profile · identity verified
Deepak K Amin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · UNION CITY, NJ · NPI 1659372829
Verified facts
What the public records show
CMS Open Payments records show Deepak K Amin, MD received $4,492.44 in general payments during 2025 across 128 reported records.
Amgen Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Verquvo.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 578 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 686 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $788.60 | 17.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $686.98 | 15.3% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $447.36 | 10.0% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $360.01 | 8.0% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $258.97 | 5.8% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $226.06 | 5.0% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $210.95 | 4.7% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $169.50 | 3.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.07 | 3.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $158.84 | 3.5% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $155.79 | 3.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $141.23 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.75 | 2.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $123.17 | 2.7% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $102.75 | 2.3% | 6 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $99.61 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $92.11 | 2.0% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.33 | 1.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.55 | 0.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $28.50 | 0.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.69 | 0.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.62 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,476.45 | 127 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $513.32 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $443.67 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $360.01 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $340.55 | 14 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $258.97 | 10 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $226.06 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $219.93 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $210.95 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $200.10 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $194.18 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $155.79 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $155.61 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $141.23 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.40 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $102.75 | 6 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $99.61 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $92.11 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $81.74 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $77.10 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.84 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.51 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $37.49 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 205 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 578 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 130 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
205 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
578 | 123 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
130 | 29 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
177 | 16 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
686 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2190 | 372 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1508 | 224 |
| Metformin Hcl | Metformin Hcl | 1204 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 1187 | 258 |
| Famotidine | Famotidine | 1087 | 223 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 896 | 194 |
| Metoprolol Succinate | Metoprolol Succinate | 704 | 144 |
| Eliquis | Apixaban | 686 | 81 |
| Diclofenac Sodium | Diclofenac Sodium | 685 | 197 |
| Omeprazole | Omeprazole | 637 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 637 | 160 |
| Gabapentin | Gabapentin | 611 | 110 |
| Fluticasone Propionate | Fluticasone Propionate | 602 | 273 |
| Jardiance | Empagliflozin | 578 | 123 |
| Losartan Potassium | Losartan Potassium | 560 | 111 |
| Lisinopril | Lisinopril | 520 | 96 |
| Carvedilol | Carvedilol | 508 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 505 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 470 | 97 |
| Memantine Hcl | Memantine Hcl | 433 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 433 | 76 |
| Furosemide | Furosemide | 417 | 90 |
| Montelukast Sodium | Montelukast Sodium | 417 | 116 |
| Ezetimibe | Ezetimibe | 410 | 94 |
| Januvia | Sitagliptin Phosphate | 400 | 61 |
| Divalproex Sodium | Divalproex Sodium | 392 | 43 |
| Alendronate Sodium | Alendronate Sodium | 374 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 365 | 84 |
| Azithromycin | Azithromycin | 332 | 240 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 309 | 59 |
| Simvastatin | Simvastatin | 274 | 40 |
| Linzess | Linaclotide | 269 | 61 |
| Valsartan | Valsartan | 269 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 268 | 46 |
| Finasteride | Finasteride | 268 | 33 |
| Trazodone Hcl | Trazodone Hcl | 268 | 39 |
| Meloxicam | Meloxicam | 263 | 102 |
| Promethazine Hcl | Promethazine Hcl | 255 | 150 |
| Mirtazapine | Mirtazapine | 250 | 56 |
| Vascepa | Icosapent Ethyl | 246 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 239 | 50 |
| Nabumetone | Nabumetone | 226 | 105 |
| Sertraline Hcl | Sertraline Hcl | 221 | 29 |
| Nifedipine Er | Nifedipine | 215 | 37 |
| Glimepiride | Glimepiride | 214 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 210 | 30 |
| Farxiga | Dapagliflozin Propanediol | 205 | 44 |
| Donepezil Hcl | Donepezil Hcl | 204 | 42 |
| Ramipril | Ramipril | 194 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 189 | 78 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 188 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 182 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 178 | 54 |
| Meclizine Hcl | Meclizine Hcl | 178 | 65 |
| Xarelto | Rivaroxaban | 177 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 166 | 30 |
| Baclofen | Baclofen | 165 | 61 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 165 | 30 |
| Ozempic | Semaglutide | 163 | 35 |
| Potassium Chloride | Potassium Chloride | 153 | 37 |
| Raloxifene Hcl | Raloxifene Hcl | 153 | 43 |
| Tradjenta | Linagliptin | 151 | 26 |
| Allopurinol | Allopurinol | 145 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 141 | 30 |
| Levetiracetam | Levetiracetam | 141 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 138 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 138 | 42 |
| Spironolactone | Spironolactone | 137 | 35 |
| Mupirocin | Mupirocin | 131 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 129 | 27 |
| Lidocaine | Lidocaine | 124 | 37 |
| Ammonium Lactate | Ammonium Lactate | 118 | 40 |
| Prednisone | Prednisone | 115 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 112 | 54 |
| Metformin Hcl Er | Metformin Hcl | 110 | 34 |
| Alprazolam | Alprazolam | 106 | 31 |
| Entresto | Sacubitril/Valsartan | 106 | 19 |
| Enalapril Maleate | Enalapril Maleate | 105 | 21 |
| Olanzapine | Olanzapine | 105 | suppressed |
| Risperidone | Risperidone | 104 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 45 |
| Ibuprofen | Ibuprofen | 100 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 74 |
| Atenolol | Atenolol | 95 | 21 |
| Mounjaro | Tirzepatide | 93 | 20 |
| Rybelsus | Semaglutide | 93 | 18 |
| Diltiazem Hcl | Diltiazem Hcl | 89 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Irbesartan | Irbesartan | 87 | 12 |
| Nystatin | Nystatin | 86 | 42 |
| Lactulose | Lactulose | 85 | 25 |
| Ranolazine Er | Ranolazine | 85 | 11 |
| Buspirone Hcl | Buspirone Hcl | 84 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 79 | 14 |
| Insulin Lispro | Insulin Lispro | 78 | 13 |
| Lubiprostone | Lubiprostone | 78 | 16 |
| Glipizide Er | Glipizide | 76 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 20 |
| Midodrine Hcl | Midodrine Hcl | 73 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 71 | 11 |
| Colchicine | Colchicine | 71 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 57 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 16 |
| Fenofibrate | Fenofibrate | 70 | suppressed |
| Ketoconazole | Ketoconazole | 69 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 68 | 18 |
| Sucralfate | Sucralfate | 68 | 19 |
| Tramadol Hcl | Tramadol Hcl | 67 | 28 |
| Hydrocortisone | Hydrocortisone | 66 | 27 |
| Naproxen | Naproxen | 66 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 22 |
| Celecoxib | Celecoxib | 64 | 16 |
| Methylprednisolone | Methylprednisolone | 64 | 52 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 11 |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 62 | 28 |
| Megestrol Acetate | Megestrol Acetate | 62 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 14 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 60 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 60 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 60 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 24 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 49 |
| Sevelamer Carbonate | Sevelamer Carbonate | 58 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 19 |
| Clonidine Hcl | Clonidine Hcl | 57 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 24 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 57 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 36 |
| Lokelma | Sodium Zirconium Cyclosilicate | 55 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Procrit | Epoetin Alfa | 55 | suppressed |
| Acarbose | Acarbose | 54 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 17 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 50 | suppressed |
| Chlorthalidone | Chlorthalidone | 50 | suppressed |
| Humulin R | Insulin Regular, Human | 50 | 13 |
| Levofloxacin | Levofloxacin | 50 | 39 |
| Risedronate Sodium | Risedronate Sodium | 50 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 48 | 17 |
| Glipizide | Glipizide | 48 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 48 | 25 |
| Latanoprost | Latanoprost | 48 | 12 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 45 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 42 | 18 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Metolazone | Metolazone | 41 | suppressed |
| Timolol Maleate | Timolol Maleate | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Alogliptin | Alogliptin Benzoate | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Epogen | Epoetin Alfa | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Budesonide | Budesonide | 37 | suppressed |
| Folic Acid | Folic Acid | 37 | 14 |
| Veltassa | Patiromer Calcium Sorbitex | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Methimazole | Methimazole | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 35 | 34 |
| Nystop | Nystatin | 35 | 18 |
| Prolia | Denosumab | 35 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 24 |
| Procto-Med Hc | Hydrocortisone | 34 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Acetylcysteine | Acetylcysteine | 32 | 16 |
| Metronidazole | Metronidazole | 32 | 24 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 16 |
| Clozapine | Clozapine | 31 | suppressed |
| Desloratadine | Desloratadine | 31 | 26 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Restasis | Cyclosporine | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Novolin R | Insulin Regular, Human | 30 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 28 | 15 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 28 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 16 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Lumigan | Bimatoprost | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 11 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Permethrin | Permethrin | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 14 |
| Verquvo | Vericiguat | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | suppressed |
| Mupirocin | Mupirocin Calcium | 16 | 11 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Xiidra | Lifitegrast | 16 | suppressed |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,492.44 · 128 records | Amgen Inc. | AREXVY, BREZTRI, BRIXADI, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, Korlym, NUPLAZID, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, RECORLEV, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VOQUEZNA, Wegovy, ZAVZPRET, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error